TR201906158T4 - Etken Maddeler ile Farmasötik-Teknolojik Yardımcı Maddeler Arasındaki Etkileşimleri Engellemek Amacıyla Kullanılan Farmasötik Preparatlar İçin Ayırıcı Katmanlar. - Google Patents

Etken Maddeler ile Farmasötik-Teknolojik Yardımcı Maddeler Arasındaki Etkileşimleri Engellemek Amacıyla Kullanılan Farmasötik Preparatlar İçin Ayırıcı Katmanlar. Download PDF

Info

Publication number
TR201906158T4
TR201906158T4 TR2019/06158T TR201906158T TR201906158T4 TR 201906158 T4 TR201906158 T4 TR 201906158T4 TR 2019/06158 T TR2019/06158 T TR 2019/06158T TR 201906158 T TR201906158 T TR 201906158T TR 201906158 T4 TR201906158 T4 TR 201906158T4
Authority
TR
Turkey
Prior art keywords
layer
separating
pharmaceutical
separating layer
core
Prior art date
Application number
TR2019/06158T
Other languages
English (en)
Inventor
Schluetermann Burkhard
Gerber Frederic
Prasch Armin
Original Assignee
Add Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Add Tech Ltd filed Critical Add Tech Ltd
Publication of TR201906158T4 publication Critical patent/TR201906158T4/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Buluş, duloksetin veya bunun farmasötik olarak kabul edilebilir bir tuzunu, özellikle de duloksetin hidroklorür içeren bir etken maddeye sahip bir çekirdeği; çekirdek üzerinde isteğe bağlı olarak bir birinci ayırıcı katmanı; birinci ayırıcı katman üzerinde birinci ayırıcı katmandan farklı ve yine isteğe bağlı olarak sübstitüye edilmiş selülozdan oluşan ve bir ya da birden fazla organik asit içeren bir estere sahip ikinci bir ayırıcı katmanı; birinci ve ikinci ayırıcı katmandan farklı, mide öz suyuna dirençli, (met)akrilik asit içeren bir polimeri kapsayan ve bileşimin dış katmanının oluşturan bir katmanı içeren granüler yapıdaki bir farmasötik preparat ile ilişkilidir. Buluş, duloksetin veya bunun farmasötik olarak kabul edilebilir bir tuzunu, özellikle de duloksetin hidroklorür içeren bir etken maddeye sahip bir çekirdeği; çekirdek üzerinde seçenek olarak bir birinci ayırıcı katmanı; birinci ayırıcı katman üzerinde birinci ayırıcı katmandan farklı ve yine isteğe bağlı olarak sübstitüye edilmiş selülozdan oluşan ve bir ya da birden fazla organik asit içeren bir estere sahip ikinci bir ayırıcı katmanı; birinci ve ikinci ayırıcı katmandan farklı, mide öz suyuna dirençli, (met)akrilik asit içeren bir polimeri kapsayan ve bileşimin dış katmanının oluşturan bir katmanı içeren granüler yapıdaki bir farmasötik preparat ile ilişkilidir.
TR2019/06158T 2009-07-17 2010-07-16 Etken Maddeler ile Farmasötik-Teknolojik Yardımcı Maddeler Arasındaki Etkileşimleri Engellemek Amacıyla Kullanılan Farmasötik Preparatlar İçin Ayırıcı Katmanlar. TR201906158T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102009033621A DE102009033621A1 (de) 2009-07-17 2009-07-17 Trennschichten für pharmazeutische Zubereitungen zur Verhinderung von Wechselwirkungen zwischen Arzneistoffen und pharmazeutisch-technologischen Hilfsstoffen

Publications (1)

Publication Number Publication Date
TR201906158T4 true TR201906158T4 (tr) 2019-05-21

Family

ID=42543200

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/06158T TR201906158T4 (tr) 2009-07-17 2010-07-16 Etken Maddeler ile Farmasötik-Teknolojik Yardımcı Maddeler Arasındaki Etkileşimleri Engellemek Amacıyla Kullanılan Farmasötik Preparatlar İçin Ayırıcı Katmanlar.

Country Status (5)

Country Link
EP (1) EP2453880B1 (tr)
DE (1) DE102009033621A1 (tr)
ES (1) ES2726049T3 (tr)
TR (1) TR201906158T4 (tr)
WO (1) WO2011006670A1 (tr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130071430A (ko) * 2010-05-25 2013-06-28 헤테로 리서치 파운데이션 둘록세틴의 경구 약제학적 조성물
ES2655622T3 (es) 2012-04-30 2018-02-20 Tillotts Pharma Ag Una formulación de fármaco de liberación retardada
CN103393615B (zh) * 2013-07-24 2015-07-15 海南华益泰康药业有限公司 一种度洛西汀肠溶小丸及其制备方法
AU2013404367B2 (en) 2013-10-29 2020-02-27 Tillotts Pharma Ag A delayed release drug formulation
CN104107169A (zh) * 2014-07-12 2014-10-22 浙江华海药业股份有限公司 一种盐酸度洛西汀药物组合物及其制备方法
GB2536936B (en) * 2015-04-01 2018-10-31 Jaguar Land Rover Ltd Damper
JP6866136B2 (ja) * 2016-11-30 2021-04-28 共和薬品工業株式会社 デュロキセチン塩酸塩を含む口腔内崩壊錠

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH27186A (en) 1989-09-07 1993-04-16 Ciba Geigy Ag Double-coated granules of disodium pamidronate
US5508276A (en) 1994-07-18 1996-04-16 Eli Lilly And Company Duloxetine enteric pellets
EP1904039A2 (en) * 2005-06-20 2008-04-02 Cadila Healthcare Ltd. Controlled release dosage formulation of duloxetine
WO2007122478A2 (en) * 2006-04-20 2007-11-01 Themis Laboratories Private Limited Multiple unit compositions
BRPI0711606A2 (pt) 2006-05-22 2012-02-14 Teva Pharma formulações de hidrocloreto de duloxetina de liberação retardada
BRPI0720958A2 (pt) * 2006-12-27 2014-03-18 Lek Pharmaceuticals Omposição de duloxetina
US20080226711A1 (en) * 2007-03-12 2008-09-18 Torrent Pharmaceuticals Ltd. Pharmaceutical compositions of duloxetine
CL2008002032A1 (es) 2007-07-13 2009-01-23 Synthon Bv Forma de dosis farmaceutica que posee una pluralidad de pellets, cada pellet comprende, un nucleo de pellet con un diametro de 600 a 1000 micrometros, capa de farmaco que comprende duloxetina o una sal y aglutinante de preferencia metil celulosa, una capa de separacion y una capa de recubrimiento enterico; proceso de preparacion

Also Published As

Publication number Publication date
WO2011006670A1 (de) 2011-01-20
EP2453880B1 (de) 2019-02-13
ES2726049T3 (es) 2019-10-01
DE102009033621A1 (de) 2011-01-20
EP2453880A1 (de) 2012-05-23

Similar Documents

Publication Publication Date Title
EA201491781A1 (ru) Лекарственный препарат с отсроченным высвобождением
JP2010535814A5 (tr)
WO2011039768A3 (en) Pharmaceutical compositions for reducing alcohol-induced dose dumping
WO2008132712A3 (en) Combination pharmaceutical compositions
UA94942C2 (ru) Фармацевтические композиции с ингибиторами dpp iv
AR082861A1 (es) Forma de dosificacion resistente a alteracion que comprende un polimero anionico
MX2010010647A (es) Proceso para preparar formulaciones de dabigatran para administracion oral.
MX352326B (es) Tableta resistente al alcohol.
WO2012002640A3 (ko) 도네페질을 함유하는 경피흡수제제
WO2009059701A3 (de) Retardtabletten mit hydromorphon
EA201071218A1 (ru) Улучшенные композиции для активных фармацевтических компонентов с плохой проницаемостью
WO2010122583A3 (en) Oral pharmaceutical compositions of acid labile substances
WO2011101866A3 (en) Gastric retention formulation containing baclofen
BRPI0908942A2 (pt) Sistemas de distribuição de fármacos compreendendo fármacos fracamente básicos e ácidos orgânicos
PE20110943A1 (es) Formulacion oral solida de alisquireno
WO2011140446A3 (en) Pharmaceutical formulations
PH12014502609A1 (en) Mutilayer coating form of orally administered pharmaceutical composition containing omega-3 fatty acid or alkyl ester thereof and statin based drug
BRPI0614545B8 (pt) composição farmacêutica de liberação controlada, seu processo de produção, forma de dosagem oral com revestimento entérico de pacreatina e uso da mesma
WO2012092486A3 (en) Modified release benzimidazole formulations
WO2013062902A3 (en) Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with atorvastatin
DE602007011316D1 (de) Pharmazeutische zusammensetzung mit antipsychotischer, antidepressiver oder antiepileptischer wirkung mit verringerter nebenwirkung
WO2011103920A3 (en) Pharmaceutical or neutraceutical formulation
WO2007097888A3 (en) Fluoroquinolone carboxylic acid salt compositions
BR112015004091A2 (pt) formulação de cápsula de compósito farmacêutico que compreende irbesartan e inibidor de hmg-coa redutase
AR061165A1 (es) Formulaciones de liberacion pulsada de fenilefrina y composiciones farmaceuticas